These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 7063089)
1. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)]. Ringwald E; Hirt D; Markstein R; Vigouret JM Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089 [No Abstract] [Full Text] [Related]
2. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)]. Allain H; Van den Driessche J; Menault F; Pape D; Reymann JM; Bentue-Ferrer D Sem Hop; 1980 Feb 8-15; 56(5-6):277-82. PubMed ID: 6243802 [TBL] [Abstract][Full Text] [Related]
3. Dopamine agonists as primary treatment in Parkinson's disease. Rinne UK Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394 [No Abstract] [Full Text] [Related]
4. [Dopamine agonists in the therapy of parkinson syndrome]. Kapfhammer HP; Rüther E Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566 [No Abstract] [Full Text] [Related]
5. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
6. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P; Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842 [TBL] [Abstract][Full Text] [Related]
7. Medications for Parkinson's disease. Whitney CM Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719 [No Abstract] [Full Text] [Related]
8. Pergolide and Parkinson's disease: new preparation. No clear benefit. Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497 [TBL] [Abstract][Full Text] [Related]
9. Drug treatment of Parkinson's disease. Callaghan N Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850 [No Abstract] [Full Text] [Related]
10. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H; Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919 [TBL] [Abstract][Full Text] [Related]
11. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease. Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688 [TBL] [Abstract][Full Text] [Related]
12. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325 [TBL] [Abstract][Full Text] [Related]
13. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575 [TBL] [Abstract][Full Text] [Related]
14. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease A short commentary. Quinn NP J Neurol; 2003 Jan; 250(1):97. PubMed ID: 12528000 [No Abstract] [Full Text] [Related]
15. New perspectives in the treatment of Parkinson's disease. LeWitt PA Clin Neuropharmacol; 1986; 9 Suppl 1():S37-54. PubMed ID: 3085929 [No Abstract] [Full Text] [Related]
17. Role of dopamine receptors in neurological drug treatment. Rinne UK Ann Clin Res; 1988; 20(5):334-9. PubMed ID: 3218905 [No Abstract] [Full Text] [Related]
18. Drug management of Parkinson's disease. Kishore A; Snow BJ Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697 [TBL] [Abstract][Full Text] [Related]